Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway (HCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01892072
Recruitment Status : Unknown
Verified July 2013 by Ming Kuang,MD,PhD, First Affiliated Hospital, Sun Yat-Sen University.
Recruitment status was:  Active, not recruiting
First Posted : July 3, 2013
Last Update Posted : July 11, 2013
Sponsor:
Collaborator:
Guangdong Province, Department of Science and Technology
Information provided by (Responsible Party):
Ming Kuang,MD,PhD, First Affiliated Hospital, Sun Yat-Sen University

Brief Summary:
The investigators study the VEGF signaling in HCC cell lines and its mechanism in HCC growth, proliferation and apoptosis.

Condition or disease Intervention/treatment
Hepatocellular Carcinoma Procedure: surgical treatment

Detailed Description:
Several studies have documented the elevated expression of VEGF, VEGFR1 and VEGFR2 in HCC cell lines and tumor tissues. Another study observed a sequential elevation of VEGF in low-grade dysplasia, high-grade dysplasia and early stage HCC. Clinical analyses have discovered the high expression of VEGF is correlated with tumor progression, vascular invasion, distal metastasis and poor prognosis. However, few studies have been conducted to investigate the VEGF signaling in HCC cells and its possible mechanism in regulating HCC growth.Therefore,we try to clarify the mechanism of VEGF signal in HCC growth,proliferation and apoptosis.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway
Study Start Date : October 2012
Estimated Primary Completion Date : October 2013
Estimated Study Completion Date : March 2014

Group/Cohort Intervention/treatment
HCC patients
Hepatocellular carcinoma patients treated by surgical treatment
Procedure: surgical treatment
all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.




Primary Outcome Measures :
  1. the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis. [ Time Frame: the day when conducting surgery (day 1) ]
    the sections would be collected as previously described.Western blot,immunohistochemistry,PCR would be conducted to find out the variation between the normal liver tissue and tumor,tumor and meta(if have).


Biospecimen Retention:   Samples Without DNA
Cut tissue into small pieces (~2 mm2)and wash in drops of saline (1x PBS). Place pieces individually into LN2 in Styrofoam cup. Transfer pieces into LN2-cooled 1.5 mL cryovial. Pour out excess LN2 from vial, then seal and keep in LN2 until freezer storage.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
hepatocellular carcinoma patients underwent surgical therapy
Criteria

Inclusion Criteria:

  1. hepatocellular patients diagnosed through biopsy;or either dynamic imagine with a diagnosis of hepatocellular carcinoma and alphafetoprotein>400μg/L;or two or more dynamic imagine with a diagnosis of hepatocellular carcinoma
  2. Child-Pugh A or B
  3. well preserved renal and hematopoietic Function
  4. receive surgical therapy
  5. achieve complete section accessed by contrast-enhanced CT

Exclusion Criteria:

  1. incomplete section
  2. remote metastasis
  3. Child-Pugh C
  4. combination with other hepatobiliary disease
  5. suffer from other tumors concurrently or in last five years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01892072


Locations
Layout table for location information
China, Guangdong
First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China, 510000
Sponsors and Collaborators
First Affiliated Hospital, Sun Yat-Sen University
Guangdong Province, Department of Science and Technology
Investigators
Layout table for investigator information
Principal Investigator: Ming Kuang, MD First Affiliated Hospital, Sun Yat-Sen University

Layout table for additonal information
Responsible Party: Ming Kuang,MD,PhD, MD,PhD, First Affiliated Hospital, Sun Yat-Sen University
ClinicalTrials.gov Identifier: NCT01892072     History of Changes
Other Study ID Numbers: k0113011-2013VEGF
First Posted: July 3, 2013    Key Record Dates
Last Update Posted: July 11, 2013
Last Verified: July 2013
Keywords provided by Ming Kuang,MD,PhD, First Affiliated Hospital, Sun Yat-Sen University:
hepatocellular carcinoma
HCC
VEGF signaling pathway
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases